NEW YORK (GenomeWeb) – ERS Genomics said today that it has licensed its CRISPR-Cas9 genome editing patents to the NMI Natural and Medical Sciences Institute at the University of Tübingen and its affiliate NMI TT Pharmaservices.

Under the terms of the non-exclusive licensing deal, NMI and NMI TT will gain access to the ERS patents in order to use them to expand their own custom cell-based research service offerings. Financial details of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.